How effective is ruxolitinib/ruxolitinib cream? Real patient feedback is coming

Ruxolitinib is a JAK1/JAK2 kinase inhibitor mainly used to treat mild to moderate atopic dermatitis (AD) and non-segmental vitiligo. As a topical drug, it reduces inflammatory response by inhibiting the JAK-STAT signaling pathway, relieves itching, skin redness and swelling, and promotes melanin recovery in patients with vitiligo. Clinical trials have shown that ruxolitinib cream is effective in improving skin symptoms with fewer side effects. It is considered a breakthrough in the treatment of atopic dermatitis and vitiligo.

In the treatment of atopic dermatitis, studies have shown that after 8 weeks of using ruxolitinib creammore than 50% of patients had significantly reduced skin inflammation, reduced itching, and restored skin barrier function. Compared with traditional topical hormones and calcineurin inhibitors, ruxolitinib cream has fewer side effects and long-term use will not cause skin atrophy or pigmentation. It is suitable for patients who cannot tolerate hormones or require long-term maintenance treatment.

In the treatment of vitiligo, ruxolitinib cream also shows good results. The study found that after using the cream for 24 weeks, the proportion of patients with facial white spots reduced by more than 50% reached 30%-50%. For vitiligo patients with a shorter course of disease, the effect is more obvious, especially the pigment recovery in the face and neck areas is faster. However, the treatment of vitiligo usually takes a long time, and ruxolitinib cream needs to be used continuously for at least 6 months to observe obvious pigment regeneration.

Although ruxolitinib cream has significant efficacy, its local side effects still need to be paid attention to, including mild skin irritation, acne-like rash, etc. Compared with oral JAK inhibitors, this cream is limited to the skin and has fewer systemic side effects, so it is considered a safer external drug.

Reference: https://www.opzelura.com/